Mirdametinib and Sirolimus

A Phase 1b/2 Study of Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma (RRMM)

What's the purpose of the trial?

Many people with relapsed refractory MM (RRMM) also have changes in their KRAS and NRAS genes. Researchers want to try a new drug treatment that targets cancer with these changed genes. 

Trial status

Not currently accepting

Phase
Phase 1/2
Enrollment
54
Last Updated

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Sirolimus
  • Mirdametinib

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Not currently accepting

Arm 1: Mirdametinib + Sirolimus

Not currently accepting

Arm 2: Mirdametinib + Sirolimus

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.